eprosartan vs glyburide
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of eprosartan and glyburide. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Concomitant administration of eprosartan and glyburide in diabetic patients did not affect 24-hour plasma glucose profiles. Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide.
Teveten
DiaBeta, Glynase
Eprosartan (Teveten) is a medicine that lowers high blood pressure. It can be used alone or with other blood pressure medicines.
Glyburide is a medicine that helps lower blood sugar in adults with type 2 diabetes. It works along with diet and exercise.
Eprosartan is used to treat high blood pressure (hypertension). It can be used by itself or with other medicines to lower your blood pressure. Lowering blood pressure helps prevent strokes, heart attacks, and kidney problems.
Glyburide is used to help control blood sugar levels in adults who have type 2 diabetes. It is prescribed in addition to diet and exercise. This medicine helps your body use insulin better, which lowers your blood sugar.
Eprosartan belongs to a class of drugs called angiotensin II receptor blockers (ARBs). It works by blocking a substance in your body that tightens blood vessels. This helps blood vessels relax, which lowers blood pressure.
Glyburide belongs to a class of drugs called sulfonylureas. It works by helping your pancreas release more insulin. Insulin then helps move sugar from your blood into your cells for energy.
- • Viral infection
- • Injury
- • Fatigue
- • Abdominal pain
- • Joint pain
- • Nausea
- • Heartburn
- • Fullness in your upper abdomen
No adverse event reports.
- Blood Glucose Increased 3,038
- Nausea 2,019
- Weight Decreased 1,537
- Diarrhoea 1,282
- Dizziness 1,201
If you become pregnant, stop taking eprosartan right away. This medicine can cause serious harm or death to your unborn baby.
Oral diabetes medicines like glyburide may increase your risk of heart problems, compared to treatment with diet alone or diet plus insulin. Talk to your doctor about the risks and benefits of taking glyburide.
Eprosartan can harm your unborn baby, even causing death. Stop taking this medicine as soon as you know you are pregnant. It is not known if eprosartan passes into breast milk, so talk to your doctor about the best way to feed your baby if you are taking this medicine.
Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if glyburide will harm your unborn baby. Talk to your doctor if you are breastfeeding.
Also Compare, Nearby Drugs
Compare eprosartan with
Compare glyburide with
How to Read This eprosartan vs glyburide Comparison
eprosartan is classified in the Angiotensin II Receptor Blocker (ARB) drug class, while glyburide sits within the Sulfonylurea class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, eprosartan has 0 submissions while glyburide has 9,077. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to eprosartan does not change how glyburide works to control your blood sugar levels.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for eprosartan or glyburide.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.